GE Healthcare and Swiss healthcare firm Roche are teaming up to explore personalized medicine in patients with Alzheimer's disease.
As part of controlled clinical trials, patients taking a Roche antiamyloid drug candidate for Alzheimer's disease will be monitored clinically for drug response using a proprietary GE PET imaging agent that measures and tracks levels of beta-amyloid, according to Roche of Basel, Switzerland, and GE of Chalfont St. Giles, U.K.
Both companies will independently analyze patient data to monitor disease progression, and then share information to validate the efficacy of both the therapeutic product and the diagnostic tool, Roche and GE said.
The firms said the data would aid both companies in submissions to regulatory authorities for approvals. Financial terms of the agreement were not disclosed.
By AuntMinnie.com staff writers
July 11, 2005
Related Reading
Medrad offers neuro coil for GE MR, July 5, 2005
GE scores Mississippi 64-slice CT order, July 4, 2005
GE taps Knapp as GM for IIS sales and marketing, June 24, 2005
GE adds volumetric mode to ultrasound, June 23, 2005
GE adds new PET/CT to portfolio, June 20, 2005
Copyright © 2005 AuntMinnie.com
